Pharmaceuticals Japan

Japan Sarcopenia Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Japan Sarcopenia Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $171.3 Mn Placeholder estimate
Estimate 2025 $184.0 Mn 5.4% of the global market
Projected 2034 $349.8 Mn 90.1% Adds $165.8 Mn over 9 forecast years
CAGR 2025–2034 7.4% Faster than 37% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 5.36% of the global market.
  • In APAC, the largest is China at $259.8 Mn.
  • Fastest growing: India at 9.7% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$165.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Sarcopenia Treatment Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $171.3 Mn — —
2025 (base) $184.0 Mn +$12.7 Mn —
2026 (forecast) $197.6 Mn +$13.6 Mn +7.4%
2027 (forecast) $212.2 Mn +$14.6 Mn +15.3%
2028 (forecast) $227.9 Mn +$15.7 Mn +23.9%
2029 (forecast) $244.8 Mn +$16.9 Mn +33.1%
2030 (forecast) $262.9 Mn +$18.1 Mn +42.9%
2031 (forecast) $282.4 Mn +$19.5 Mn +53.5%
2032 (forecast) $303.2 Mn +$20.9 Mn +64.8%
2033 (forecast) $325.7 Mn +$22.4 Mn +77%
2034 (forecast) $349.8 Mn +$24.1 Mn +90.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $3.43 Bn
  2. North America $1.91 Bn
  3. US $1.32 Bn
  4. Europe $631.6 Mn
  5. APAC $635.8 Mn
  6. China $259.8 Mn
  7. Canada $251.0 Mn
  8. Japan (this report) $184.0 Mn
  9. Middle East $153.4 Mn
  10. Latin America $137.9 Mn
  11. Germany $113.3 Mn
  12. UK $98.1 Mn
  13. Brazil $95.7 Mn
  14. France $90.8 Mn
  15. Spain $74.2 Mn
  16. Italy $73.7 Mn
  17. Ecuador $70.8 Mn
  18. India $64.5 Mn
  19. Saudi Arabia $62.4 Mn
  20. Mexico $49.6 Mn
  21. Africa $47.0 Mn
  22. Australia $41.8 Mn
  23. Russia $35.6 Mn
  24. New Zealand $31.7 Mn
  25. South Africa $24.9 Mn
  26. UAE $15.0 Mn
  27. Egypt $11.1 Mn
  28. Philippines $6.9 Mn
  29. Hong Kong $6.3 Mn
  30. Malaysia $6.0 Mn
  31. Singapore $3.9 Mn
  32. Thailand $3.6 Mn
  33. Kenya $2.2 Mn

Report snapshot

Japan Sarcopenia Treatment Market Analysis at a glance
Market size, 2025$184.0 Mn placeholder estimate
Forecast, 2034$349.8 Mn placeholder estimate
Growth (CAGR), 2025–20347.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, product and end user (see all)
Key playersAbbott Laboratories, Nestle, Regeneron Pharmaceuticals, Scholar Rock, Biophytis (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials1 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Sarcopenia Treatment Market Analysis Executive Summary

Sarcopenia treatment aims to slow or reverse age-related loss of muscle mass and strength with nutrition, exercise and new medicines.

Key segments of the sarcopenia Treatment market include treatment (Nutritional Supplements, Exercise Programs and Pharmacological Therapy) and product (Protein and Amino Acids, Vitamin D and Myostatin Inhibitors).

Bar chart: Japan Sarcopenia Treatment market size, 2024–2034, placeholder estimates. $171.3 Mn in 2024, $184.0 Mn in 2025 and $349.8 Mn in 2034, 7.4% CAGR.
Japan Sarcopenia Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Sarcopenia Treatment Market Dynamics

Market Growth Drivers

An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the sarcopenia Treatment market. Older adults and their families are spending more on staying active and independent.

Opportunity

Preventive care, personalised plans based on biomarkers and home-based services give the sarcopenia Treatment market room to grow, especially in fast-ageing countries in Asia and Europe.

Market Restraints

Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the sarcopenia Treatment market.

Competitive Landscape for Sarcopenia Treatment Market in Japan

The sarcopenia Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Sarcopenia Treatment Market in Japan

Sarcopenia Treatment in Japan: rules, payment and research

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 1 study on Sarcopenia Treatment that is recruiting, active or about to start in Japan.⁠[3] People aged 65 and over: 30.0% of people in 2025, the latest WHO figure for Japan.⁠[4]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for sarcopenia Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Sarcopenia Treatment right now, from free public sources.

Clinical trials

1 active trial in Japan

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Abbott Laboratories 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Exosystems 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 63 papers since 2021 (worldwide)

  1. Treatment-dependent association between sarcopenia and ADL at discharge after osteoporotic vertebral fractures. Journal of bone and mineral metabolism, 2026
  2. Formononetin mitigates age-related sarcopenia by blocking mitochondrial ferroptosis via SIRT1/PGC-1α signaling. The international journal of biochemistry & cell biology, 2026
  3. Icariin ameliorates sarcopenia via activation of the estrogen receptor α/fatty acid transport protein 1 pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026
  4. Protective effects of irisin in sarcopenia: a promising treatment. Journal of orthopaedic translation, 2026
  5. How Pragmatic Are Sarcopenia Intervention Studies? A Systematic Review. Journal of cachexia, sarcopenia and muscle, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Sarcopenia Treatment in context

Japan compared

  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[1]
  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[3]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Sarcopenia Treatment market in Japan?
Placeholder estimate: about $184.0 Mn in 2025, rising to about $349.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Sarcopenia Treatment market in Japan growing?
Placeholder estimate: about 7.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Sarcopenia Treatment market report cover?
The report splits the market by treatment (Nutritional Supplements, Exercise Programs, Pharmacological Therapy, Hormone Therapy), product (Protein and Amino Acids, Vitamin D, Myostatin Inhibitors) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Sarcopenia Treatment market?
Key players include Abbott Laboratories, Nestle, Regeneron Pharmaceuticals, Scholar Rock and Biophytis.
What is driving the Sarcopenia Treatment market?
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the sarcopenia Treatment market. Older adults and their families are spending more on staying active and independent.
Who regulates Sarcopenia Treatment in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on Sarcopenia Treatment are running in Japan?
1 study is recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
What does WHO report for Japan?
People aged 65 and over: 30.0% of people in 2025, the latest WHO figure. Source: WHO Global Health Observatory, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
How much research is published on Sarcopenia Treatment?
PubMed lists 63 papers on Sarcopenia Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Sarcopenia Treatment in Japan? Our analysts can size it for your plan. Talk to us See the public data People aged 65 and over for every country, free. Open the Public Health Dashboard

From our blog

Bone and Joint Health: Supplements for an Ageing Population1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence… Eye Health Supplements: Screens, Ageing and Vision2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a… Herbal Supplements: Quality, Safety and Trust170 of 194 WHO member states report use of traditional medicine. Herbal products are popular, but quality and…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Japan

See all
Same topic, other categories

Related on geriatric and nutrition

See the topic